期刊论文详细信息
Journal of Diabetes Investigation
Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
Yoshinobu Kondo2  Shinobu Satoh2  Joe Nagakura2  Masayo Kimura2  Uru Nezu1 
[1] Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan;Department of Endocrinology and Metabolism, Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan
关键词: Glucagon stimulation test;    Liraglutide;    Type 2 diabetes;   
DOI  :  10.1111/jdi.12082
来源: Wiley
PDF
【 摘 要 】

Abstract

Aims/Introduction

To define a set of criteria using indices of β-cell function, including results from the glucagon stimulation test, for liraglutide introduction in patients with type 2 diabetes.

Materials and Methods

In the present retrospective cohort study, patients were included in our analysis if their β-cell function had been evaluated with a glucagon stimulation test and a 24-h urinary C-peptide (U-CPR) excretion test before switching from insulin therapy to liraglutide monotherapy. The efficacy of liraglutide was determined by the extent to which glycemic control was achieved or if glycated hemoglobin levels were maintained at <7.0% after liraglutide monotherapy for 24 weeks.

Results

Liraglutide was effective in 36 of 77 patients. In the liraglutide-effective cases, the following parameters were higher: fasting C-peptide (CPR0) levels, C-peptide levels 6 min after glucagon stimulation (CPR6), the C-peptide index (CPI; CPR0 × 100/fasting plasma glucose) and stimulated C-peptide index (S-CPI; CPR6 × 100/plasma glucose 6 min after glucagon stimulation). U-CPR did not differ between liraglutide-effective and liraglutide-ineffective cases. Using receiver operating characteristic analysis adjusted for baseline characteristics, the independent cut-off value for effective liraglutide introduction was 0.72 for CPI and 1.92 for S-CPI.

Conclusions

Evaluation of β-cell function using the glucagon stimulation test is useful for determining the efficacy of liraglutide introduction in patients with type 2 diabetes.

【 授权许可】

Unknown   
© 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd

【 预 览 】
附件列表
Files Size Format View
RO202107150013969ZK.pdf 140KB PDF download
  文献评价指标  
  下载次数:3次 浏览次数:2次